Changes in androgens during treatment with four low-dose contraceptives

Contraception

Volumn 53, Issue 3, 1996, Pages 171-176

  Coenen, C M H ^a   Thomas, C M G ^a   Borm, G F ^a   Hollanders, J M G ^a   Rolland, R ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

Author keywords

androgens; oral contraceptives

Indexed keywords

ALBUMIN; ANDROGEN; ANDROSTENEDIONE; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTODENE; HYDROXYPROGESTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRANSCORTIN;

ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; HYPERVENTILATION; LUTEAL PHASE; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SPOTTING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TESTOSTERONE BLOOD LEVEL; VULVA PRURITUS;

EID: 0029930874     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(96)00006-6     Document Type: Article

References (23)

1. Inman WHW, Vessey MP, Westerhom B, et al. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety and Drugs. Br Med J 1970;2:203-9.
2. Meade TW, Greenberg G, Thompson SG. Progestens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-μg oestrogen preparations. Br Med J 1980;280:1157-61.
3. Thoregood M, Vessey MP. An epidemiologic survey of cardiovascular disease in women taken oral contraceptives. Am J Obstet Gynecol 1990;163:274-81.
4. Lidegaard Ø. Oral contraception and risk of cerebral thromboembolic attack: Results of case-control study. Br Med J 1993;306:956-63.
5. Ellis J. Low-dose oral contraceptives: Progestins potency, androgenicity and atherogenic potential. Clin Therapeutics 1986;8:607-18.
6. Philips A, Hahn DW, Mcguire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol 1992;167:1191-6.
7. Valkenburg HA, Hofman A, Klein F, Groustra FN. Een epidemiologisch onderzoek naar risico-indicatoren voor hart-en vaatziekten (EPOZ). Bloeddruk, serum-cholesterolgehalte, Quetelet-index en rookgewoonten in een open bevolking van vijf jaar en ouder. Ned T Geneesk 1980;124:183-9.
8. Thomas CMG, Berg van den RJ, Rolland R. Measurement of serum testosterone: Results of the "Farmos" SHBG IRMA kit and the "Coat-A-Count" free testosterone kit compared with salivary testosterone. Clin Chem 1986;32;702.
9. EEC Note for Guidance: Good Clinical Practice for trials on medicinal products in the European community, CPMP Working Party on Efficacy of Medical Product. Pharmacol Toxicol 1990;67:361-72.
10. Hammond GL, Langley M, Robinson PA. A liquid phase immuno radiometric assay (IRMA) for human sex hormone-binding globulin. J Steroid Biochem 1985;86: 405-14.
11. Dony JMJ, Smals AGH, Rolland R, Fauser BJCM, Thomas CMG. Effect of aromatase inhibition by δ-1-testolactone on basal and luteinizing hormone-releasing hormone-stimulated pituitary and gonadal hormonal function in oligospermic men. Fertil Steril 1985;43:787-92.
12. Van Duren BPJ. The infertile couple: some cycle and sperm characteristics. Academic Thesis, Catholic University of Nijmegen, 1988.
13. Reijnders FJL. The influence of 17α-hydroxyprogesterone carproate on early pregnancy. Academic Thesis, Catholic University of Nijmegen, 1988.
14. Welch RE. Stepwise multiple comparison procedures. J Am Stat Assoc 1977;72:566-75.
15. Bauer P. Multiple testing in clinical trials. Stat Med 1991;10:871-90.
16. Krauss RM, Burkman RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992;167:1177-84.
17. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity of progesterone and androgen receptor binding of progestogens used in oral contraceptives. Contraception 1988;38:325-32.
18. Runnebaum B, Rabe T. New progestogens in oral contraceptives. Am J Obstet Gynecol 1987;157:1059-63.
19. Kafrissen ME. A norgestimate-containing oral contraceptive: review of clinical studies. Am J Obstet Gynecol 1992;167:1196-202.
20. Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynec 1992;167:1177-84.
21. Collins DC. Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives. Am J Obstet Gynecol 1994;170:1508-13.
22. Murphy AA, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of low dose oral contraceptive on gonadotropins, androgens, and sex hormone-binding globulin in nonhirsute women. Fertil Steril 1990;53;35-9.
23. Adams DB, Gold AR. Rise in female-initiated sexual activity at ovulation and its suppression by oral contraceptives. New Engl J Med 1978;229:1145-50.